27399557|t|359 Delayed Treatment of Ruptured Arteriovenous Malformations: Is It Ok to Wait?
27399557|a|Emergent surgery on a ruptured brain arteriovenous malformation (AVM) is indicated for a large hematoma in an acutely deteriorating patient. The majority of ruptured AVMs, however, present in clinically stable patients with neurological deficits. Controversy exists with respect to the timing of treatment for ruptured AVMs in these stable patients. This study aims to determine the safety of delaying AVM treatment in clinically stable patients by investigating the rate of rehemorrhage in a cohort of patients with ruptured brain AVMs. Patients presenting to our institution from January 2000 to December 2015 with ruptured brain AVMs treated at least 4 weeks posthemorrhage were included in the analysis. Exclusion criteria were ruptured AVMs that required emergent surgery involving AVM resection, previous treatment at another institution, or subacute AVM treatment. The primary outcome measure was time from initial hemorrhage to rehemorrhage. Patient follow-up data were included up until the point of AVM treatment. Of the 103 ruptured AVMs (49 M:54 F) meeting inclusion criteria, the median time from rupture to treatment or rehemorrhage was 112 days (interquartile range [IQR]: 110). Six (5.8%) patients rehemorrhaged in a median of 248 days (IQR: 1331). Two of these patients rehemorrhaged on the same day of their index hemorrhage. The total at-risk period was 19 445 patient - days, yielding a rehemorrhage risk of 11.3% per patient - year, or 0.93% per patient - month. Our data support stabilizing a patient after the initial AVM rupture. It is safe to closely monitor the patient, initiate the rehabilitation process, and then, in a semielective manner, bring the patient back for treatment. Delaying intervention for 4 weeks after initial hemorrhage subjects the patient to a low (<1%) risk of rehemorrhage.
27399557	4	21	Delayed Treatment	T033	C3693346
27399557	25	33	Ruptured	T037	C3203359
27399557	34	61	Arteriovenous Malformations	T191	C0334533
27399557	81	89	Emergent	T078	C0750573
27399557	90	97	surgery	T061	C0543467
27399557	103	111	ruptured	T037	C3203359
27399557	112	117	brain	T023	C0006104
27399557	118	144	arteriovenous malformation	T191	C0334533
27399557	146	149	AVM	T191	C0334533
27399557	176	184	hematoma	T046	C0018944
27399557	199	212	deteriorating	T033	C1457868
27399557	213	220	patient	T101	C0030705
27399557	238	246	ruptured	T037	C3203359
27399557	247	251	AVMs	T191	C0334533
27399557	273	283	clinically	T080	C0443178
27399557	284	290	stable	T080	C0205360
27399557	291	299	patients	T101	C0030705
27399557	305	326	neurological deficits	T033	C0521654
27399557	377	386	treatment	T169	C1522326
27399557	391	399	ruptured	T037	C3203359
27399557	400	404	AVMs	T191	C0334533
27399557	414	420	stable	T080	C0205360
27399557	421	429	patients	T101	C0030705
27399557	436	441	study	T062	C2603343
27399557	464	470	safety	T068	C0036043
27399557	474	482	delaying	T079	C0205421
27399557	483	486	AVM	T191	C0334533
27399557	487	496	treatment	T169	C1522326
27399557	500	510	clinically	T080	C0443178
27399557	511	517	stable	T080	C0205360
27399557	518	526	patients	T101	C0030705
27399557	530	543	investigating	T169	C1292732
27399557	556	568	rehemorrhage	T046	C0019080
27399557	574	580	cohort	T098	C0599755
27399557	584	592	patients	T101	C0030705
27399557	598	606	ruptured	T037	C3203359
27399557	607	612	brain	T023	C0006104
27399557	613	617	AVMs	T191	C0334533
27399557	619	627	Patients	T101	C0030705
27399557	646	657	institution	T093	C2607850
27399557	663	670	January	T080	C3829466
27399557	679	687	December	T080	C3830550
27399557	698	706	ruptured	T037	C3203359
27399557	707	712	brain	T023	C0006104
27399557	713	717	AVMs	T191	C0334533
27399557	737	742	weeks	T079	C0439230
27399557	743	757	posthemorrhage	T037	C0919874
27399557	779	787	analysis	T062	C0936012
27399557	789	807	Exclusion criteria	T169	C0680251
27399557	813	821	ruptured	T037	C3203359
27399557	822	826	AVMs	T191	C0334533
27399557	841	849	emergent	T078	C0750573
27399557	850	857	surgery	T061	C0543467
27399557	868	871	AVM	T191	C0334533
27399557	872	881	resection	T061	C0015252
27399557	892	901	treatment	T169	C1522326
27399557	913	924	institution	T093	C2607850
27399557	929	937	subacute	T079	C0205365
27399557	938	941	AVM	T191	C0334533
27399557	942	951	treatment	T169	C1522326
27399557	957	980	primary outcome measure	T080	C3274433
27399557	985	989	time	T079	C0040223
27399557	995	1002	initial	T079	C0205265
27399557	1003	1013	hemorrhage	T046	C0019080
27399557	1017	1029	rehemorrhage	T046	C0019080
27399557	1031	1038	Patient	T101	C0030705
27399557	1039	1048	follow-up	T058	C1522577
27399557	1090	1093	AVM	T191	C0334533
27399557	1094	1103	treatment	T169	C1522326
27399557	1116	1124	ruptured	T037	C3203359
27399557	1125	1129	AVMs	T191	C0334533
27399557	1150	1168	inclusion criteria	T080	C1512693
27399557	1174	1185	median time	T079	C1254367
27399557	1191	1198	rupture	T037	C3203359
27399557	1202	1211	treatment	T169	C1522326
27399557	1215	1227	rehemorrhage	T046	C0019080
27399557	1236	1240	days	T079	C0439228
27399557	1242	1261	interquartile range	T081	C1711350
27399557	1263	1266	IQR	T081	C1711350
27399557	1286	1294	patients	T101	C0030705
27399557	1295	1308	rehemorrhaged	T046	C0019080
27399557	1314	1320	median	T081	C0876920
27399557	1328	1332	days	T079	C0439228
27399557	1334	1337	IQR	T081	C1711350
27399557	1359	1367	patients	T101	C0030705
27399557	1368	1381	rehemorrhaged	T046	C0019080
27399557	1394	1397	day	T079	C0439228
27399557	1413	1423	hemorrhage	T046	C0019080
27399557	1435	1449	at-risk period	T079	C1948053
27399557	1461	1468	patient	T101	C0030705
27399557	1471	1475	days	T079	C0439228
27399557	1488	1500	rehemorrhage	T046	C0019080
27399557	1519	1526	patient	T101	C0030705
27399557	1529	1533	year	T079	C0439234
27399557	1548	1555	patient	T101	C0030705
27399557	1558	1563	month	T079	C0439231
27399557	1569	1573	data	T078	C1511726
27399557	1596	1603	patient	T101	C0030705
27399557	1622	1625	AVM	T191	C0334533
27399557	1626	1633	rupture	T037	C3203359
27399557	1649	1676	closely monitor the patient	T061	C0513791
27399557	1691	1705	rehabilitation	T169	C0034992
27399557	1761	1768	patient	T101	C0030705
27399557	1778	1787	treatment	T169	C1522326
27399557	1789	1797	Delaying	T079	C0205421
27399557	1817	1822	weeks	T079	C0439230
27399557	1837	1847	hemorrhage	T046	C0019080
27399557	1861	1868	patient	T101	C0030705
27399557	1874	1888	low (<1%) risk	T081	C3538919
27399557	1892	1904	rehemorrhage	T046	C0019080